首页> 外文期刊>Gynecologic and obstetric investigation >Progesterone Receptor Isoforms, Nuclear Corepressor-1 and Steroid Receptor Coactivator-1 and B-Cell Lymphoma 2 and Akt and Akt Phosphorylation Status in Uterine Myomas after Ulipristal Acetate Treatment: A Systematic Immunohistochemical Evaluation
【24h】

Progesterone Receptor Isoforms, Nuclear Corepressor-1 and Steroid Receptor Coactivator-1 and B-Cell Lymphoma 2 and Akt and Akt Phosphorylation Status in Uterine Myomas after Ulipristal Acetate Treatment: A Systematic Immunohistochemical Evaluation

机译:普通酮受体同种型,核心投压器-1和类固醇受体共粘膜-1和B细胞淋巴瘤2和akt和Akt磷酸化状态在尿醋酸脲酸盐治疗后子宫肌瘤中:系统免疫组化评价

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Objective: To investigate whether ulipristal acetate (UPA) treatment modifies the expression of progesterone receptor (PR), its nuclear cofactors steroid receptor coactivator-1 (SRC 1) and nuclear corepressor-1 (NCoR1), prosurvival factor B-cell lymphoma 2 (Bcl-2), and Akt in uterine myomas. Patients: Prospective study of 59 women with symptomatic myomas undergoing myomectomy. Forty-two patients were treated preoperatively with UPA; the remaining 17 were not and they served as controls. Method: Tissue microarrays were obtained from surgical specimens and immunohistochemistry was performed. Blinded quantification of expression of PR (PR-A vs. PR-B), coactivator SRC1 and corepressor NCoR1, and prosurvival factor Bcl-2, and Akt and evaluation of Akt phosphorylation levels. Results: Compared with the control group, UPA does not alter PR protein levels or expression patterns in myomas, and the PR-A/PR-B ratio was similar, as well as cytoplasmic or nuclear expression of cofactors SRC1 and NCoR1. Bcl-2 was heterogeneously expressed throughout the samples and no significant modification in expression was evidenced. No significant difference was found in Akt expression and phosphorylation between treated and untreated myomas. Conclusion: This study did not find any significant change in the expression of the studied factors in myomas after UPA exposure. In conclusion, various theories on myomas cells proposed on the basis of in vitro studies are not supported in vivo. (C) 2017 S. Karger AG, Basel
机译:目的:探讨伯哌酸酯(UPA)治疗是否改变孕酮受体(PR)的表达,其核心辅因子类固醇受体共粘膜-1(SRC 1)和核心投压器-1(Ncor1),脱抗因子B细胞淋巴瘤2( Bcl-2)和子宫肌瘤的Akt。患者:59例患有Myomectomy的症状Myomas的前瞻性研究。四十二名患者用UPA术前治疗;剩下的17岁不是,他们担任控制。方法:从外科样品中获得组织微阵列,并进行免疫组织化学。致盲定量Pr(PR-A与PR-B),共粘膜SRC1和核心压缩机Ncor1,以及耐久性因子Bcl-2,以及Akt磷酸化水平的评价。结果:与对照组相比,UPA不改变PR蛋白水平或乳糜蛋白酶的表达模式,并且PR-A / PR-B比对于Cofactors SRC1和Ncor1的细胞质或核表达。在整个样品中,Bcl-2在整个样品中表达,并且证明了表达中没有明显的修饰。在治疗和未经治疗的眼部之间的AKT表达和磷酸化中没有发现显着差异。结论:本研究没有发现USMA暴露后研究中研究因素表达的任何显着变化。总之,在体外研究的基础上提出的各种理论在体外研究的基础上不支持。 (c)2017年S. Karger AG,巴塞尔

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号